The initial success of the copyright undeniably revolutionized the pharmaceutical landscape, but betting in companies heavily reliant on generic versions presents a uncertain picture. While early profits were significant, the end of patents and the emergence of less expensive alternatives have eroded the customer base. Therefore, a thorough assessm